$0.22
(Market cap
$887 Mln
Revenue (TTM)
$65 Mln
P/E Ratio
--
P/B Ratio
3.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1
-
Face value
--
-
Shares outstanding
104,721,098
7 Years Aggregate
CFO
$-252.18 Mln
EBITDA
$-352.32 Mln
Net Profit
$-396.69 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Personalis (PSNL)
| 6.4 | 35.7 | 2.3 | 79.4 | 57.4 | -17.4 | -- |
|
BSE Sensex*
| -9.7 | -0.2 | -7.0 | -6.4 | 7.4 | 8.6 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Personalis (PSNL)
| 37.7 | 173.0 | 6.1 | -86.1 | -61.0 | 235.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Personalis (PSNL)
|
8.5 | 887.0 | 64.5 | -95.6 | -151.2 | -44.8 | -- | 3.5 |
| 75.0 | 10,557.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 17.3 | |
| 76.9 | 10,446.2 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 50.2 | 12,605.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.6 | 6.4 | |
| 119.0 | 15,772.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 68.3 | 8,103.6 | 1,508.5 | 348.8 | 57.0 | 96.4 | 24 | 36.9 | |
| 299.5 | 8,827.7 | 417.3 | 225.0 | 42.8 | 18.6 | 40 | 6.9 | |
| 517.3 | 11,925.8 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.0 | |
| 432.8 | 12,360.6 | 2,678.3 | 460.4 | 21.1 | 103.2 | 27.3 | 20.7 | |
| 343.6 | 9,578.0 | 0.0 | -326.5 | -- | -37.2 | -- | 6.8 |
Shareholding Pattern
View DetailsAbout Personalis (PSNL)
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD),... therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California. Read more
-
President, CEO & Director
Mr. Christopher M. Hall
-
President, CEO & Director
Mr. Christopher M. Hall
-
Headquarters
Fremont, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Personalis (PSNL)
What is the current share price of Personalis Inc (PSNL) Today?
The share price of Personalis Inc (PSNL) is $8.47 (NASDAQ) as of 22-May-2026 19:39 EDT. Personalis Inc (PSNL) has given a return of 57.45% in the last 3 years.
What is the current PB & PE ratio of Personalis Inc (PSNL)?
Since, TTM earnings of Personalis Inc (PSNL) is negative, P/E ratio is not available.
The P/B ratio of Personalis Inc (PSNL) is 3.48 times as on 22-May-2026, a 19 discount to its peers’ median range of 4.32 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-8.72
|
2.71
|
|
2024
|
-4.20
|
1.68
|
|
2023
|
-0.93
|
0.78
|
|
2022
|
-0.80
|
0.42
|
|
2021
|
-9.63
|
2.02
|
What is the 52 Week High and Low of Personalis Inc (PSNL)?
The 52-week high and low of Personalis Inc (PSNL) are Rs 11.50 and Rs 3.84 as of 25-May-2026.
What is the market cap of Personalis Inc (PSNL)?
Personalis Inc (PSNL) has a market capitalisation of $ 887 Mln as on 22-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Personalis Inc (PSNL)?
Before investing in Personalis Inc (PSNL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.